Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received a consensus rating of “Moderate Buy” from the fifteen brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $12.2308.

Several analysts have recently weighed in on CMPX shares. Citigroup began coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They set an “outperform” rating on the stock. Compass Point set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, October 8th. Leerink Partnrs raised Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. Finally, Citizens Jmp assumed coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 target price for the company.

Compass Therapeutics Trading Down 0.2%

Shares of NASDAQ CMPX opened at $5.37 on Friday. The business has a fifty day simple moving average of $4.86 and a 200 day simple moving average of $3.80. The firm has a market capitalization of $955.11 million, a price-to-earnings ratio of -11.93 and a beta of 1.45. Compass Therapeutics has a one year low of $1.33 and a one year high of $5.86.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. On average, research analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Several large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its holdings in Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the last quarter. Creative Planning acquired a new stake in shares of Compass Therapeutics during the second quarter worth approximately $30,000. Strs Ohio acquired a new stake in shares of Compass Therapeutics during the first quarter worth approximately $34,000. Apollon Wealth Management LLC bought a new position in shares of Compass Therapeutics in the third quarter valued at approximately $35,000. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Compass Therapeutics in the 3rd quarter worth approximately $37,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.